UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2022 » Volume 30, issue 1 (110) » PROTOCOL FOR THE TREATMENT OF PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS BY INJECTION OF BONE MARROW STROMAL CELLS IN THE CONDITIONS OF THE INSTITUTE OF NEUROLOGY, PSYCHIATRY AND NARCOLOGY OF THE NSAN OF UKRAINE

PROTOCOL FOR THE TREATMENT OF PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS BY INJECTION OF BONE MARROW STROMAL CELLS IN THE CONDITIONS OF THE INSTITUTE OF NEUROLOGY, PSYCHIATRY AND NARCOLOGY OF THE NSAN OF UKRAINE

Authors

Type of Article

  • Scientific Article

In the Section

  • TO HELP A PRACTICING PHYSICIAN
Index UDK:

Abstract

diagnosis amyotrophic lateral sclerosis (ALS).
Code for ICH 10: G12.2.
Patient category: patients with ALS.
Recognition protocol for doctors who treat patients with ALS.
Meta Protocol: creation of an algorithm for ALS therapy by injecting bone marrow stromal cells (BMSCs), slowing down the progression of the disease.

Pages

  • 75-79

Year / Issue

Download PDF

References

  1. Voloshyna NP Amyotrophic lateral sclerosis: scientific and methodical publication / NP Voloshyna, OV Yegorkina, IK Gaponov, OV Gorbunov. Kyiv : Europe print, 2010. 32 с.
  2. Egorkina, O. V. Amyotrophic lateral sclerosis: the main modern directions in treatment / O. V. Egorkina, N. P. Voloshina, V. V. Gaponov // International Neurological Journal. 2008. № 6(22). С. 95-103.
  3. Amyotrophic lateral sclerosis : a guide for doctors / ed. by I. A. Zavalishin. A. Zavalishin. Moscow : Eurasia+, 2007. 447 с.
  4. Voloshina N. P. Discussion issues of therapy of amyotrophic lateral sclerosis / N. P. Voloshina, O. V. Egorkina // Journal of NeuroNews. 2009. № 6 (17). С. 15-17; № 7(18). 2009. С. 21-25 (continued).
  5. Majoor-Krakauer D. Genetic epidemiology of amyotrophic lateral sclerosis / D. Majoor-Krakauer, P. J. Willems, A. Hofman // Clin. Genet. 2003. 63 (2). P.  83—101. DOI: https://doi.org10.1046/j.0009-9163.2002.00001.x.
  6. Molecular mechanisms of motor neuron disease development / C. A. Skvortsova, S. A. Limborskaya, K. B. Sokolov, G. H. Levitsky // Journal of Neurology and Psychiatry. C. C. Korsakov. 2005. Т. 102. № 4. C. 68-76.
  7. Al-Chalabi A. The epidemiology of  ALS: a  conspiracy of genes, environment and time / A. Al-Chalabi, O. Hardiman // Nat Rev Neurol. 2013. 9(11). Р. 617—628. DOI: https://doi.org10.1038/nrneurol.2013.203.
  8. Vasenina E. E. E. E. Vasenina O. S. Levin // Modern therapy in psychiatry and neurology. 2013. № 3(4). С. 39-46.
  9. Excitotoxicity in ALS: Overstimulation, or overreaction? / A. E. King, A. Woodhouse, M. T. Kirkcaldie, J. C. Vickers // Exp Neurol. 2016. 275. Pt 1. Р. 162—71. DOI: https://doi.org10.1016/j.expneurol.2015.09.019.
  10. Bräuer S. Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis / S. Bräuer, V. Zimyanin, A. Hermann // J Neural Transm (Vienna). 2018. 125(4). Р. 591—613. DOI: https://doi.org10.1007/s00702-018-1851-y.
  11. Ramesh N. Autophagy dysregulation in ALS: When protein aggregates get out of hand / N. Ramesh, U. B. Pandey // Front Mol Neurosci. 2017. 10. Р. 263. DOI: https://doi.org10.3389/fnmol.2017.00263.
  12. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis / K. G. Hooten, D. R. Beers, W. Zhao [et al.] // Appel Neurotherapeutics. 2015. 12(2). Р. 364—375. DOI: https://doi.org10.1007/s13311-014-0329-3.
  13. Ugras S. E. RNA-binding proteins in amyotrophic lateral sclerosis and neurodegeneration / S.   Ugras, J.  Shorter  // Neurol Res Int. 2012: 432780. DOI: https://doi.org10.1155/2012/432780.
  14. De Vos K. J. Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? / K. J. De Vos, M. Hafezparast // Neurobiol Dis. 2017. 105. Р. 283—299. DOI: https://doi.org1016/j.nbd.2017.02.004.
  15. Smith E. The role of  mitochondria in  amyotrophic lateral sclerosis / E. F. Smith, P. J. Shaw, K. J. De // Vos Neurosci Lett. 2017 Jun 30. DOI: https://doi.org10.1016/j.neulet.2017.06.052.
  16. Multilineage potential of adult human mesenchymal stem cells / M. F. Pittenger, A. M. Mackay, S. C. Beck [et al.] // Science. 1999. 284. Р. 143—147. DOI: https://doi.org10.1126/science.284.5411.143.
  17. Human mesenchymal stem cells express neural genes, suggesting a neural predisposition / N. R. Blondheim, Y. S. Levy, T. Ben-Zur [et al.] // Stem Cells Dev. 2006. 15. Р. 141—164. DOI: https://doi.org10.1089/scd.2006.15.141.
  18. Kassis I. Bone marrow mesenchymal stem cells: agents of immunomodulation and neuroprotection / I. Kassis, A. VakninDembinsky, D. Karussis // Curr Stem Cell Res Ther.  6. Р. 63—68. DOI: https://doi.org10.2174/157488811794480762.
  19. Uccelli A. Mesenchymal stem cells: a new strategy for immunosuppression? / A. Uccelli, V. Pistoia, L. Moretta // Trends Immunol. 2007. 28. Р. 219—226. DOI: https://doi.org10.1016/j.it.2007.03.001.
  20. Ben-Hur T. Immunomodulation by neural stem cells / T. Ben-Hur // J Neurol Sci. 2008. 265. Р. 102—104. DOI: https://doi.org10.1016/j.jns.2007.05.007.
  21. Nauta A. J. Immunomodulatory properties of mesenchymal stromal cells / A. J. Nauta, W. E. Fibbe // Blood. 2007. 110. Р. 3499—3506. DOI: https://doi.org10.1182/blood-2007-02-069716.
  22. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis / I. Kassis, N. Grigoriadis, B. Gowda-Kurkalli [et ]  // Arch Neurol. 2008. 65. Р.  753—761. DOI: https://doi.org10.1001/archneur.65.6.753.
  23. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy / E. Zappia, S. Casazza, E. Pedemonte [et al.] // Blood. 2005. 106. Р. 1755— 1761. DOI: https://doi.org10.1182/blood-2005-04-1496.
  24. Uccelli A. Mesenchymal stem cells in health and disease / A. Uccelli, L. Moretta, V. Pistoia // Nat Rev Immunol. 2008. 8. Р. 726—736. DOI: https://doi.org10.1038/nri2395.
  25. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis / V. K. Harris, Q. J. Yan, T. Vyshkina [et al.] // J Neurol Sci. 2012. 313. Р. 167—177. DOI: https://doi.org10.1016/j.jns.2011.08.036.
  26. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases / A. Uccelli, A. Laroni, M. S. Freedman // Lancet Neurol. 2011. 10. Р. 649—656. DOI: https://doi.org10.1016/S1474-4422(11)70121-1.
  27. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis / S. Pluchino, A. Quattrini, E. Brambilla [et al.] // Nature. 2003. 422: 688—94. DOI: https://doi.org10.1038/nature01552.
  28. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates / S. Pluchino, E. Blezer, S. Amadio [et al.] // Ann Neurol. 2009. 66. Р. 343—354. DOI: https://doi.org10.1002/ana.21745.
  29. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis / T. Ben-Hur, O. Einstein, R. Mizrachi-Kol [et al.] // Glia. 2003. 41. Р. 73—80. DOI: https://doi.org10.1002/glia.10159.
  30. Karussis D. Clinical experience with stem cells and other cell therapies in neurological diseases / D. Karussis, P. Petrou, I. Kassis // J  Neurol Sci. 2013. 324. Р.  1—9. DOI: https://doi.org10.1016/j.jns.2012.09.031.
  31. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats / J. Chen, Y. Li, L. Wang [et al.] // J Neurol Sci. 2001. 189. Р. 49—57. DOI: https://doi.org10.1016/s0022-510x(01)00557-3.
  32. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis / D. Karussis, C. Karageorgiou, A. Vaknin-Dembinsky [et al.] // Arch Neurol. 2010. 67. Р. 1187—1194. DOI: https://doi.org10.1001/archneurol.2010.248.
  33. A randomized trial of mesenchymal stem cells in multiple system atrophy / P. H. Lee, J. E. Lee, H. S. Kim [et al.] // Ann Neurol. 2012. 72. Р. 32—40. DOI: https://doi.org10.1002/ana.23612.
  34. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials / P. Petrou, Y. Gothelf, Z. Argov [et al.] // JAMA Neurol. 2016. 73. Р. 337—344. DOI: https://doi.org10.1001/jamaneurol.2015.4321.
  35. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, biomarker results / J. D. Berry, M. E. Cudkowicz, A. J. Windebank [et al.] Neurology. 2019. 93. Р. 2294—2305. DOI: https://doi.org10.1212/WNL.0000000000008620.
  36. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases / D. Karussis, I.  Kassis, B.    Kurkalli, S. Slavin // J Neurol Sci. 2008. 265. Р. 131—135. DOI: https://doi.org10.1016/j. jns.2007.05.005.
  37. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials / J. D. Glass, V. S. Hertzberg, N. M. Boulis [et al.] // Neurology. 2016. 87. Р. 392—400. DOI: https://doi.org10.1212/WNL.0000000000002889.
  38. Voloshina N. P., Vasilovskiy V. V., Mikulinskiy Yu. E., Schegelskaya E. A. Autoterapiya kletkami stromyi kostnogo mozga (KSKM), indutsirovannyimi v nervnyie, bolnyih s hronicheskimi zabolevaniyami TsNS (rasseyannyiy skleroz, bolezn Parkinsona). Ukrainskyi neirokhirurhichnyi zhurnal. 2003. No. 3. URL: https://cyberleninka.ru/article/n/autoterapiya-kletkami-stromy-kostnogo-mozga-indutsirovannymi-v-nervnye-bolnyh-s-hronicheskimi-zabolevaniyami-tsnsrasseyannyy-skleroz.
  39. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion / E. Eggenhofer, V. Benseler, A. Kroemer [et al.] // Front Immunol. 2012. 3. Р. 297. DOI: https://doi.org10.3389/fimmu.2012.00297.
  40. Voloshyna N. P., Vasylovskyi V. V., Mikulynskyi Yu. Yu., Shchehelska O. A. Patent UA 68711 A. «Sposib likuvannia khvorykh na rozsiianyi skleroz» vid 02.10.2003. Kyiv. Ukrpatent.
  41. Voloshina N. P., Vasilovskiy V. V. Eticheskie voprosyi v lechenii bolnyih rasseyannyim sklerozom (autoterapiya stromalnyimi kletkami kostnogo mozga, indutsirovannyimi v nervnyie). Kultura narodov Prichernomorya. 2004. No. 56. T. 2. R. 185—186.
  42. Karussis D. The potential use of stem cells in multiple sclerosis: an overview of the preclinical experience / D. Karussis, I. Kassis // Clin Neurol Neurosurg. 2008. 110. P. 889—896. DOI: https://doi.org10.1016/j.clineuro.2008.02.008.
  43. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I/II safety and feasibility study / O. Fernandez, G. Izquierdo, V. Fernandez [et al.] // PLoS ONE. 2018. 13: e0195891. DOI: https://doi.org10.1371/journal.pone.0195891.
  44. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis / S. Llufriu, M. Sepulveda, Y. Blanco[et al.] // PLoS ONE. 2014. 9: e113936. DOI: https://doi.org10.1371/journal.pone.0113936.
  45. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials / P. Petrou, Y. Gothelf Z. Argov [et al.] // JAMA Neurol. 2016 Mar. 73(3). Р. 337—344. DOI: https://doi.org10.1001/jamaneurol.2015.4321.

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»